tiprankstipranks
Regen Biopharma (RGBP)
OTHER OTC:RGBP
US Market

Regen Biopharma (RGBP) Income Statement

64 Followers

Regen Biopharma Income Statement

Last quarter (Q ), Regen Biopharma's total revenue was $31.64K, a decrease of -46.43% from the same quarter last year. In Q, Regen Biopharma's net income was $-122.47K. See Regen Biopharma’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Sep 23Sep 22Sep 21Sep 20Sep 19
Total Revenue
$ 126.56K$ 126.56K$ 125.52K$ 61.19K$ 110.00K$ 110.00K
Cost of Revenue
--$ 117.25K---
Gross Profit
$ 126.56K$ 126.56K$ 8.27K$ 61.19K--
Operating Expense
$ 266.02K$ 813.51K$ 347.87K$ 261.96K$ 319.32K$ 866.78K
Operating Income
$ -112.04K$ -686.95K$ -339.61K$ -200.77K$ -209.32K$ -756.78K
Net Non Operating Interest Income Expense
$ -60.98K$ -58.58K$ -138.26K$ -315.78K$ -942.93K$ -1.70M
Other Income Expense
$ 209.21K$ -1.90M$ -3.28M$ 5.40M$ 4.57M$ -165.44K
Pretax Income
$ -413.99K$ 1.16M$ 2.74M$ -6.77M$ 3.41M$ -2.62M
Tax Provision
--$ 300.00K---
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
$ -386.56K$ 1.02M$ 2.44M$ -6.77M$ 2.73M$ -2.62M
Basic EPS
$ -0.10$ 0.29--$ <0.01$ >-0.01
Diluted EPS
$ -0.10$ 0.29--$ <0.01$ >-0.01
Basic Average Shares
$ 12.57M$ 3.54M$ 4.70B$ 2.01M$ 1.41B$ 2.07B
Diluted Average Shares
$ 12.57M$ 3.54M$ 4.70B$ 2.01M$ 1.41B$ 2.07B
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
----$ 18.55K$ 60.00K
Total Expenses
$ 266.02K$ 813.51K$ 465.12K$ 261.96K$ 319.32K$ 866.78K
Net Income From Continuing And Discontinued Operation
$ -626.43K$ 1.16M$ 2.44M$ -6.77M$ 2.73M$ -2.62M
Normalized Income
$ -568.70K$ 913.64K--$ -602.13K$ -2.46M
Interest Expense
----$ 942.93K$ 1.70M
EBIT
$ -353.01K$ 1.22M$ 2.88M$ -6.45M$ 4.36M$ -920.92K
EBITDA
$ -259.15K$ 1.22M$ 2.95M$ -6.45M$ 4.36M$ -920.92K
Currency in USD

Regen Biopharma Earnings and Revenue History

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis